The PEERLESS II Study (NCT06055920)

🧪 Interventions in This Study

• FlowTriever System (DEVICE)
• Anticoagulation Agents (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (77 Sites)

Showing the first 25 of 77 sites.

• UAB Division of Cardiovascular Disease — Birmingham, Alabama
• Brookwood Medical Center — Birmingham, Alabama
• Huntington Memorial Hospital — Pasadena, California
• University of Colorado, Denver — Aurora, Colorado
• Yale University — New Haven, Connecticut
• HCA FL Largo Medical Center — Largo, Florida
• AdventHealth Orlando — Orlando, Florida
• Emory University — Atlanta, Georgia
• Northwestern University — Chicago, Illinois
• McLaren Greater Lansing — Lansing, Michigan
• Saint Luke's Hospital of Kansas City — Kansas City, Missouri
• Mercy Hospital Springfield — Springfield, Missouri
• Nebraska Medical Center — Omaha, Nebraska
• Virtua Health — Camden, New Jersey
• SUNY, The University of Buffalo/Gates Vascular — Buffalo, New York
• Northwell Health — New York, New York
• Jamaica Hospital — Queens, New York
• University of Rochester Medical Center — Rochester, New York
• Stony Brook University Hospital — Stony Brook, New York
• Montefiore Medical Center — The Bronx, New York
• University of Cincinnati Medical Center — Cincinnati, Ohio
• The Cleveland Clinic Foundation — Cleveland, Ohio
• Ohio State University - Wexner Medical Center — Columbus, Ohio
• St. Luke's University Hospital — Bethlehem, Pennsylvania
• AHN Saint Vincent Hospital — Erie, Pennsylvania

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Pulmonary Embolism

• Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism — Birmingham, Alabama
• Novel α2-Antiplasmin Inactivation for Lysis of Intravascular Thrombi (NAIL-IT) Trial — Phoenix, Arizona
• Comparing Electrical Impedance Tomography to Computed Tomographic Angiography — Loveland, Colorado
• Peripheral Systemic Thrombolysis Versus Catheter Directed Thrombolysis for Submassive PE — Bay Shore, New York
• Michigan Emergency Department Improvement Collaborative (MEDIC) Alert; Pulmonary Embolism (PE) — Ann Arbor, Michigan
• Pulmonary Embolism International THrOmbolysis Study-3 — Linz,

Explore by condition: All Pulmonary Embolism clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.